A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION) (NCT06925750)
An Open-label Extension Study to Evaluate Safety and Tolerability of Sotatercept (MK-7962) Administered Using a Weight-banded Approach in Participants With Pulmonary Arterial Hypertension (PAH) on Standard of Care
🩺 Plain-English Summary (8th-Grade Level)
Researchers are looking for other ways to treat pulmonary arterial hypertension (PAH). Sotatercept is a study medicine that is designed to treat PAH. A past study, MK-7962-024 (LIGHTRAY) (NCT06664801), learned about the safety and effects of sotatercept in people with PAH. One of the goals of that study was to learn about sotatercept when given at a dose (amount) based on the weight range a person is in (weight-banded doses) compared to when given based on a person's exact weight. This is an extension study, which means people who took part in MK-7962-024 (LIGHTRAY) may be able to join this study. In this extension study, people will get weight-banded doses of sotatercept. The main goal of this study is to learn about the safety of weight-banded doses of sotatercept and if people tolerate it over a longer period of time.
Who can join: Review the eligibility criteria below.
Location: University of Colorado Anschutz Medical Campus-University of Colorado Hospital Cardiac and Vascular ( Site 1930) — Aurora, Colorado
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (73 Sites)
Showing the first 25 of 73 sites.
- University of Colorado Anschutz Medical Campus-University of Colorado Hospital Cardiac and Vascular ( Site 1930) — Aurora, Colorado
- University of Kansas Medical Center ( Site 1928) — Kansas City, Kansas
- University of New Mexico Health Sciences Center - Department of Internal Medicine ( Site 1916) — Albuquerque, New Mexico
- Centro Medico Capital ( Site 0002) — La Plata, Buenos Aires
- Instituto de Investigaciones Clinicas Mar del Plata ( Site 0006) — Mar del Plata, Buenos Aires
- Instituto Medico Rio Cuarto ( Site 0010) — Río Cuarto, Córdoba Province
- Instituto de Cardiologia Juana F. Cabral ( Site 0008) — Corrientes,
- Hospital Provincial Jose Maria Cullen ( Site 0005) — Santa Fe,
- Royal Prince Alfred Hospital ( Site 0103) — Camperdown, New South Wales
- Westmead Hospital ( Site 0100) — Westmead, New South Wales
- Wesley Research Institute ( Site 0101) — Auchenflower, Queensland
- The Alfred Hospital ( Site 0102) — Melbourne, Victoria
- IUCPQ ( Site 0208) — Québec, Quebec
- Guangdong Provincial People's Hospital-Cardiology ( Site 2000) — Guangzhou, Guangdong
- The Second Xiangya Hospital of Central South University ( Site 2002) — Changsha, Hunan
- Shanghai Pulmonary Hospital ( Site 2004) — Shanghai, Shanghai Municipality
- Yan an Hospital of Kunming City ( Site 2011) — Kunming, Yunnan
- Clinica Colsanitas - Sede Reina Sofia ( Site 0303) — Bogotá, Bogota D.C.
- Fundacion Santa Fe de Bogota ( Site 0302) — Bogotá, Bogota D.C.
- IMAT S.A.S ( Site 0301) — Montería, Departamento de Córdoba
- Clínica Imbanaco S.A.S ( Site 0304) — Cali, Valle del Cauca Department
- Vseobecna fakultni nemocnice v Praze ( Site 0400) — Prague, Praha 2
- CHU Bordeaux Haut-Leveque ( Site 0501) — Pessac, Aquitaine
- C.H.U Hôpital Nord ( Site 0500) — Marseille, Bouches-du-Rhone
- CHU de Rouen ( Site 0503) — Rouen, Haute-Normandie
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Pulmonary Arterial Hypertension
- A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension — Phoenix, Arizona
- Pulmonary Vascular Disease Phenomics Program PVDOMICS — Tucson, Arizona
- An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH) — Jacksonville, Florida
- A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension — Aurora, Colorado
- ADAPT - A Patient Registry of the Real-world Use of Orenitram® — Fresno, California
Explore by condition: All Pulmonary Arterial Hypertension clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.